DAPA-PedHKD Trial
Cross-source consensus on DAPA-PedHKD Trial from 1 sources and 5 claims.
1 sources · 5 claims
Other
Other
Highlighted claims
- DAPA-PedHKD is a multicentre, open-label, randomised crossover trial. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)
- The trial enrolls 67 paediatric patients across 21 Chinese hospitals. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)
- The trial runs from March 2025 to March 2027, with enrolment closing in May 2026. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)
- Each treatment sequence includes 12 weeks of active treatment, a 4-week RAASi-only washout, and 12 weeks of the alternate treatment. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)
- The crossover design assigns participants equally to two treatment sequences. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)